Clinical trial NCT06795139: Pilot of a Trial Enrollment Diversity Dashboard
Official title: Feasibility Pilot of a Trial Enrollment Diversity Dashboard (TEDD)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Leukemia
Acute Leukemia
Keywords: Leukemia
Acute Leukemia
Clinical Trial Diversity
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: American Society of Clinical Oncology
First posted: 2025-01-27
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.

Detailed description: This study is about testing a tool called the Trial Enrollment Diversity Dashboard (TEDD) to see if it can help increase diversity in cancer clinical trials, specifically for leukemia. Clinical trials are important for developing new cancer treatments, but not all groups are equally represented in these trials. This can lead to treatments that may not work as well for everyone.

The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed.

The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard.

It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months.

The National Cancer Institute is providing funding for this research study.

Eligibility criteria: Inclusion Criteria Medical Professionals:

* Physician, nurse practitioner, or physician assistant

  -≥10% clinical effort (or one ½ day of clinic per week for those working \<1 FTE)
* Treats adult patients with leukemia or related diseases at the study sites
* Ability to understand and willingness to provide informed consent
* Age 18 or older

Inclusion Criteria Participant Population:

* Age ≥18 years old
* Diagnosis of leukemia, lymphoma, myeloma, or related diseases
* Seen by a physician for this diagnosis at one of the study sites

Exclusion Criteria Medical Professionals:

-Listed member of the research team

Exclusion Criteria Participant Population:

-Participants without the diagnoses of interest listed above, participants not seen at the study sites.

Primary outcomes:
measure: TEDD Utilization Rate
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Andrew Hantel, MD
role: PRINCIPAL_INVESTIGATOR
References: